149 compounds. Every one graded.

Once-weekly amylin analogue for weight loss

Cagrilintide is a long-acting acylated amylin analogue developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. It mimics the pancreatic hormone amylin to reduce appetite, slow gastric emptying, and promote satiety. In clinical trials, it has been studied both as a monotherapy and in combination with semaglutide (as CagriSema), demonstrating meaningful and sustained body weight reduction.

Dual amylin-GLP-1 therapy for superior weight loss

Cagrisema is a fixed-ratio combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), each at 2.5 mg per dose. This dual-hormone therapy is designed to provide additive and potentially synergistic effects on appetite suppression, glycemic control, and body weight reduction beyond what either agent achieves alone. It is currently under clinical investigation by Novo Nordisk for the treatment of obesity and type 2 diabetes.

The master anabolic and lipolytic growth hormone

Human Growth Hormone (HGH) is a 191-amino acid peptide hormone naturally secreted by the anterior pituitary gland that regulates growth, body composition, and metabolism. In clinical and performance contexts, recombinant HGH (rhGH) is administered exogenously to mimic or augment endogenous GH signaling. It is one of the most studied anabolic and lipolytic compounds in endocrinology, with established uses in GH deficiency, muscle-wasting conditions, and anti-aging protocols.

Dual GLP-1/glucagon agonist for metabolic health

Mazdutide is a dual GLP-1/glucagon receptor co-agonist peptide developed by Innovent Biologics, originally derived from oxyntomodulin. It simultaneously activates both GLP-1 and glucagon receptors to produce robust reductions in body weight, blood glucose, and hepatic fat. Clinical trials in China have demonstrated significant efficacy for obesity and type 2 diabetes management.

Triple-action metabolic optimization

Burn fat faster while feeling less hungry.

GLP-1 receptor agonist for appetite suppression

A GLP-1 receptor agonist approved for type 2 diabetes management and chronic weight management, demonstrating substantial and sustained weight reduction in large clinical trials.

AMPK activator mimicking endurance exercise effects

AICAR (Acadesine) is a nucleoside analog and potent AMPK activator that mimics the cellular energy-depletion state, triggering a cascade of metabolic adaptations including enhanced fatty acid oxidation and mitochondrial biogenesis. It has been extensively studied for its ability to improve endurance performance, insulin sensitivity, and metabolic flexibility without physical exercise. Originally developed as a cardioprotective agent, it has attracted significant interest in the performance and longevity research communities.

Fat-targeting hGH fragment for metabolic support

AOD9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (amino acids 176–191), developed originally by Monash University as an anti-obesity drug. It mimics the lipolytic (fat-burning) effects of growth hormone without stimulating IGF-1 production or promoting cell proliferation. Research suggests it stimulates fat breakdown and inhibits fat formation, with a favorable safety profile compared to full-length hGH.

Synergistic GH pulse amplifier for body and recovery

CJC-1295 (without DAC) + Ipamorelin is a synergistic peptide blend combining a growth hormone-releasing hormone (GHRH) analogue with a selective growth hormone secretagogue. Together, they stimulate the pituitary gland to release growth hormone in a pulsatile, physiologically natural manner. This combination is widely used for body composition improvement, recovery, anti-aging, and sleep quality enhancement.

Natural GH Pulses for Growth and Recovery

CJC-1295 without DAC (also known as Modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone in a pulsatile, physiologically natural pattern. It consists of the first 29 amino acids of GHRH with four key amino acid substitutions that enhance stability and receptor affinity compared to the native peptide. It is widely used in research settings for its potential to promote lean muscle growth, fat loss, recovery, and anti-aging effects.

Long-acting GHRH analog for sustained GH release

CJC-1295 with DAC is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH) that incorporates a Drug Affinity Complex (DAC) to dramatically extend its half-life. By binding covalently to serum albumin, it maintains sustained elevation of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) for up to two weeks per injection. It is used in research settings to study GH secretion, body composition changes, and recovery processes.

Long-acting GLP-1 receptor agonist

Weekly GLP-1 agonist for diabetes & weight management.

Synthetic exendin-4 GLP-1 agonist

Exendin-4 synthetic peptide for glycemic control.

Potent GH secretagogue with cardiac benefits

Hexarelin Acetate is a synthetic hexapeptide and potent growth hormone secretagogue (GHS) that stimulates pituitary release of growth hormone (GH) by mimicking the action of ghrelin. It binds to the GHS-R1a receptor with high affinity and also exhibits direct cardioprotective effects independent of GH release. Developed originally as a potential treatment for GH deficiency, it is one of the most potent GH-releasing peptides studied in clinical research.

Targeted fat-loss fragment of growth hormone

HGH Fragment 176-191 is a synthetic peptide derived from amino acids 176–191 of the C-terminus of human growth hormone (hGH). It was specifically engineered to retain the lipolytic (fat-burning) properties of hGH while eliminating its growth-promoting and insulin-desensitizing effects. Research, primarily in animal models, suggests it stimulates fat breakdown and inhibits the formation of new fat cells.

Lipotropic blend for fat loss and liver health

Lipo-C is a lipotropic injection blend combining several compounds—typically methionine, inositol, choline, carnitine, and B vitamins—designed to support fat metabolism and liver function. It promotes the mobilization and breakdown of fat deposits, particularly in the liver. The formulation is commonly used in weight loss programs to enhance lipolysis and improve metabolic efficiency.

GLP-1 analog for daily weight management

Short-acting GLP-1 agonist for weight loss & diabetes.

Short-acting GLP-1 for post-meal control

Short-acting GLP-1 agonist for post-meal glucose.

Potent tanning and libido melanocortin agonist

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) originally developed at the University of Arizona. It potently activates melanocortin receptors to stimulate skin tanning, increase sexual arousal, and suppress appetite. Unlike natural α-MSH, its cyclic structure confers greater receptor affinity and metabolic stability.

FDA-approved GHRH analog for fat reduction

GHRH analog for visceral fat reduction & GH elevation.

Dual GIP/GLP-1 receptor agonist

Dual GIP/GLP-1 agonist for superior weight loss & glycemic control.

Targeted fat-depot destruction via vascular apoptosis

Adipotide (also called FTTP) is an experimental peptidomimetic compound designed to selectively destroy the blood supply to white adipose tissue by targeting prohibitin, a protein highly expressed on the vasculature feeding fat cells. Originally developed at MD Anderson Cancer Center, it demonstrated dramatic fat loss in obese rhesus monkeys without dietary restriction. It remains a research compound with no approved human clinical use.

Targeted fat-depot elimination via vascular apoptosis

Adipotide is a pro-apoptotic peptidomimetic designed to selectively destroy the blood supply feeding white adipose tissue (WAT), causing fat cell death through targeted vascular disruption. It was developed at MD Anderson Cancer Center primarily as an anti-obesity compound and has shown dramatic fat loss in non-human primate studies. Human clinical data remains extremely limited, and it is considered a research compound only.

Third-generation GH secretagogue with refined selectivity

GHRP-3 is a synthetic hexapeptide and member of the growth hormone releasing peptide family, designed to stimulate the pulsatile release of growth hormone (GH) from the anterior pituitary gland. It acts primarily as a ghrelin mimetic and GHS-R1a agonist, amplifying natural GH secretion pulses. GHRP-3 is structurally related to GHRP-2 and GHRP-6 but exhibits a modified amino acid sequence intended to reduce appetite-stimulating side effects while maintaining GH secretagogue potency.

Endogenous GLP-1 for meal-time satiety

Native GLP-1 peptide for acute appetite control.

Endogenous Y2 receptor agonist for satiety

Natural appetite-suppressing gut peptide.

Exercise mimetic targeting mitochondrial energy pathways

SLU-PP-322 is a synthetic small-molecule agonist of estrogen-related receptors (ERRα, ERRβ, and ERRγ) developed at Saint Louis University. It mimics the metabolic effects of sustained aerobic exercise at the cellular level, promoting mitochondrial biogenesis, fatty acid oxidation, and endurance capacity without physical activity. In preclinical animal studies, it has demonstrated significant improvements in exercise performance, fat metabolism, and cardiac function.

HGH fragment for lipolysis stimulation

HGH fragment for localized fat metabolism.

Experimental GH fragment targeting fat metabolism

Frag 17-23 is a short synthetic peptide fragment derived from amino acids 17 through 23 of the human growth hormone (hGH) sequence. It is hypothesized to retain lipolytic properties similar to larger hGH fragments while being structurally distinct from the more widely studied Frag 176-191. Evidence for its efficacy in humans remains largely anecdotal, with minimal published research specific to this fragment.

Pituitary GH secretagogue for growth and recovery

GHRP-4 is a synthetic hexapeptide ghrelin mimetic designed to stimulate the pituitary gland's release of endogenous growth hormone. It belongs to the same family as GHRP-2 and GHRP-6 but is a less extensively characterized analog with a modified structure aimed at optimizing GH release with a potentially reduced appetite-stimulating side effect profile. Research on GHRP-4 specifically is limited compared to its better-studied relatives, and most mechanistic understanding is extrapolated from the broader GHRP class.